Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

Technology appraisal guidance
Reference number: TA333
Published: 25 February 2015

Renal cell carcinoma (advanced) - axitinib: response to consultee, commentator and public comments on the Appraisal Consultation Document

Renal cell carcinoma (advanced) - axitinib: response to consultee, commentator and public comments on the Appraisal Consultation Document

Renal cell carcinoma (advanced) - axitinib: response to consultee, commentator and public comments on the Appraisal Consultation Document
28 March 2013
(253.45 Kb 13 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 25 March 2013